

CURRICULUM VITAE

Brian C Joondeph, MD, MPS

(updated 2/01/21)

EDUCATION AND TRAINING:

COLLEGE: Cornell University, Ithaca, NY
B.A. Mathematics, 1980

MEDICAL SCHOOL: Northwestern University, Chicago, IL
M.D., 1984

INTERNSHIP: Cook County Hospital, Chicago, IL
Transitional, July 1984 - June 1985

RESIDENCY: University of Illinois, Chicago, IL
Ophthalmology, July 1985 - June 1988

FELLOWSHIPS: Bascom Palmer Eye Institute, Miami, FL
Retina-Vitreous, July 1988 - June 1989

University of Illinois, Chicago, IL
Uveitis, July 1989 - December 1989

GRADUATE SCHOOL: University of Denver, Denver, CO
Masters in Healthcare Leadership, 2013
Academic Excellence Award
(Healthcare Policy and Regulatory Leadership)

CHIEF RESIDENCY: University of Illinois, Chicago, IL
Assistant Professor, July 1989 - Dec. 1989

BOARD CERTIFICATION: American Board of Ophthalmology; (May 1990)
National Board of Medical Examiners; (April 1985)
Federal Licensing Examination (FLEX); (June 1985)

LICENSURE: Colorado #41445
Medical Council of New Zealand #29438

PROFESSIONAL SOCIETIES: American Academy of Ophthalmology (Achievement Award 2015)
American College of Surgeons
American Uveitis Society
Macula Society
Retina Society
American Society of Retina Specialists (Honor Award 2002)

CURRENT POSITIONS: Partner, Colorado Retina Associates, PC
Denver, CO (July 2003-present)
Executive Committee (2010-2013), President (2012-2013)
Executive Committee (2014-2016)

Consultant Ophthalmologist, Department of Ophthalmology
Auckland District Health Board
Auckland, New Zealand (2009 – present)

PAST POSITIONS: Clinical Professor of Ophthalmology
Rocky Vista University College of Osteopathic Medicine
Parker, CO (2009-2016)

Consultant Ophthalmologist
Goodland Regional Medical Center, Goodland, KS (2004-18)

Consultant Ophthalmologist and Associate Professor
Department of Ophthalmology, The University of Auckland
Auckland, New Zealand (2001-2003)

Partner, Vitreo-Retinal Consultants, PC
Detroit, MI (1990-2001)

Assistant Clinical Professor of Ophthalmology
Wayne State University School of Medicine
Detroit, MI (1990-2001)

Assistant Clinical Professor of Ophthalmology
Michigan State University College of Osteopathic Medicine
Lansing, MI (1997-2001)

HOSPITAL APPOINTMENTS: Porter Adventist Hospital, Denver, CO (July 2003 – present)
Lowry Surgery Center, Denver, CO (2005-2019)
Harvard Park Surgery Center, Denver, CO (2005-present)
Lincoln Surgery Center, Parker, CO (2009-present)
Red Rocks Surgery Center, Golden, CO (2011-present)
Rocky Mountain Surgery Center, Englewood, CO (2019-present)

PROFESSIONAL ACTIVITIES: Lowry Surgery Center Interim Medical Director (May-July 2012)
Lowry Surgery Center Board of Managers (2011 – 2019)
Lincoln Surgery Center Medical Advisory Committee (2013 – 2018)
Lincoln Surgery Center Board of Managers (2018 – present)
Examiner – American Board of Ophthalmology (2014 – present)
Peer Review Consultant – Physicians Review Organization (2015 – present)

FACULTY APPOINTMENTS: Clinical Professor of Ophthalmology
Rocky Vista University College of Osteopathic Medicine
Parker, CO 2009-16

University of Auckland, Auckland, New Zealand
Associate Professor - Department of Ophthalmology, 2001-03

Wayne State University School of Medicine, Detroit, MI
Assistant Clinical Professor - Dept. of Ophthalmology, 1990-2001

Michigan State University College of Osteopathic Medicine, Lansing, MI
Assistant Clinical Professor - Dept. Of Surgery, 1997-2001

University of Illinois, Chicago, IL
Assistant Professor - Dept. of Ophthalmology, 1989

PUBLICATIONS:

1. Sanders DR, Joondeph BC, Hutchins R, Schwartz D, Yeh T, Peyman GA: Studies on the Blood-Aqueous Barrier After Argon Laser Photocoagulation of the Iris. *Ophthalmology* 90:169-174, 1983.
2. Wilensky JT, Joondeph BC: Variation in Visual Field Measurements with an Automated Perimeter. *American Journal of Ophthalmology* 97:328-331, 1984.
3. Wilensky JT, Joondeph BC: Reply to Letter to the Editor: Variation in Visual Field Measurements with an Automated Perimeter by Werner EB. *American Journal of Ophthalmology* 97:802, 1984.
4. Joondeph BC, Joondeph HC: Purulent Anterior Chamber Endophthalmitis Following Paracentesis. *Ophthalmic Surgery* 17:91-93, 1986.
5. Joondeph BC, Spigelman AV, Pulido JS: Ocular Trauma from Break Dancing. *Archives of Ophthalmology* 104:176-177, 1986.
6. Joondeph BC, Peyman GA, Mafee MF, Joondeph HC: Magnetic Resonance Imaging and Retinal Tacks. *Archives of Ophthalmology* 105:1479-1480, 1987.
7. Joondeph BC, Joondeph HC, Flood TP: Foveal Neovascularization in Diabetic Retinopathy. *Archives of Ophthalmology* 105:1672-1675, 1987.
8. Joondeph BC: Granular Corneal Dystrophy - Nikon's Resident Diagnosis of the Month. *Ophthalmology Times* 13:14, 1987.
9. Miller A, Joondeph BC, Peyman GA, Fiscella R: Intravitreal Toxicity of Bovine Cartilage Extract (Catrix-S): A Biologic Response Modifier. *Annals of Ophthalmology* 20:100-104, 1988.
10. Joondeph BC, Peyman GA, Khoobehi B, Yue BY: Liposome-Encapsulated 5-Fluorouracil in the Treatment of Proliferative Vitreoretinopathy. *Ophthalmic Surgery* 19:252-256, 1988.
11. Joondeph HC, Joondeph BC: Posterior Tractional Retinal Breaks Complicating Branch Retinal Vein Occlusion. *Retina* 8:136-140, 1988.
12. Joondeph BC, Goldberg MF: Familial Iris Melanosis - A Misnomer? *British Journal of Ophthalmology* 73:289-93, 1989.
13. Joondeph BC, Flynn HW, Miller D, Joondeph HC: A New Culture Method for Infectious Endophthalmitis. *Archives of Ophthalmology* 107:1334-1337, 1989.
14. Heilskov T, Joondeph BC, Olsen K, Blankenship GW: Endophthalmitis Following Scleral Fixation of a Posterior Chamber Intraocular Lens. *Archives of Ophthalmology* 107:1427, 1989.
15. Joondeph BC, Joondeph HC, Blair NP: Retinal Macroaneurysms Treated with the Yellow Dye Laser. *Retina* 9:187-192, 1989.

16. Joondeph BC, Flynn HW, Blankenship GW, Glaser BM, Stern WH: The Surgical Management of Giant Retinal Tears with the Cannulated Extrusion Needle. *American Journal of Ophthalmology* 108:548-553, 1989.
17. Joondeph BC, Blankenship GW: Hemostatic Effects of Air Versus Fluid in Diabetic Vitrectomy. *Ophthalmology* 96:1701-1707, 1989.
18. Joondeph BC, Young TL, Saran BR: Multiple Scleral Ruptures Following Blunt Ocular Trauma. *American Journal of Ophthalmology* 108:744, 1989.
19. Gass JDM, Joondeph BC: Observations Concerning Patients with Suspected Impending Macular Holes. *American Journal of Ophthalmology* 109:638-646, 1990.
20. Foster JA, Lam S, Joondeph BC, Sugar J: Suprachoroidal Dislocation of a Posterior Chamber Intraocular Lens. *American Journal of Ophthalmology* 109:731-732, 1990.
21. Joondeph BC, Flynn HW: Management of Subretinal Foreign Bodies With a Cannulated Extrusion Needle. *American Journal of Ophthalmology* 110:250-253, 1990.
22. Joondeph BC, Tessler HH: Multifocal Choroiditis. *International Ophthalmology Clinics* 30:286-290, 1990.
23. Jennings T, Fuller T, Vukich JA, Lam TT, Joondeph BC, Ticho B, Blair NP, Edward DP: Transscleral Contact Retinal Photocoagulation with an 810 nm Semiconductor Diode Laser. *Ophthalmic Surgery* 21:492-496, 1990.
24. Feist RM, Lim JI, Joondeph BC, Plugfelder SC, Mieler WF, Ticho BH, Resnick K: Penetrating Ocular Injury from Contaminated Eating Utensils. *Archives of Ophthalmology* 109:63-66, 1991.
25. Fox GM, Joondeph BC, Flynn HW, Pflugfelder SC, Roussel TJ: Delayed Onset Pseudophakic Endophthalmitis. *American Journal of Ophthalmology* 111:163-173, 1991.
26. Joondeph HC, Joondeph BC: Reply to Letter to the Editor by Russell S: *Retina* 10:321, 1991.
27. Joondeph BC: A New Technique for the Administration of Intraoperative Periocular Steroids. *American Journal of Ophthalmology* 111:647-648, 1991.
28. Joondeph BC: Blunt Ocular Trauma. *Seminars in Ophthalmology* 5:85-97, 1991.
29. Schatz H, Fong ACO, McDonald HR, Johnson RN, Joffe L, Wilkinson CP, DeLaey JJ, Yannuzzi LA, Wendel RT, Joondeph BC, Angioletti LV, Meredith TA: Cilioretinal Artery Occlusion in Young Adults with Central Retinal Vein Occlusion. *Ophthalmology* 98:594-601, 1991.
30. Joondeph BC, Tessler HH: Clinical Course of Multifocal Choroiditis: Photographic and Angiographic Evidence of Disease Recurrence. *Annals of Ophthalmology* 23:424-429, 1992.
31. Joondeph HC, Joondeph BC, Mulcahy T: Comparison of Three Permanent Intraocular Magnets. *Retina* 12:270-272, 1992.

32. Joondeph BC: A New Tantalum Clip for Securing a Silicone Encircling Band. *Ophthalmic Surgery* 23:711, 1992.
33. Joondeph BC, Joondeph HC: Reply to Letter to the Editor: Permanent Intraocular Magnets by Kuhn F, et al. *Retina* 13:177, 1993.
34. Joondeph BC, Joondeph HC: Vitrectomy Specimen Culture Technique. *Ophthalmology* 100:1597-1598, 1993.
35. Proctor BD, Joondeph BC: Bilateral Anterior Uveitis: A Feature of Streptokinase-induced Serum Sickness. *New England Journal of Medicine* 330:576-577, 1994.
36. Foster RE, Rubsamen PE, Joondeph BC, Flynn HW, Smiddy WS: Concurrent Endophthalmitis and Retinal Detachment. *Ophthalmology* 101:490-498, 1994.
37. Claringbold TV, Joondeph BC: Diabetic Eye Disease (CD-ROM Review). *Journal of the American Medical Association* 277:1565, 1997.
38. Aaberg TM, Rubsamen PE, Joondeph BC, Flynn HW: Chronic Postoperative Gram Negative Endophthalmitis. *Retina* 17:260-262, 1997.
39. Joondeph BC: Ophthalmology (Book Review). *Journal of the American Medical Association* 281:1546-1546, 1999.
40. Pan TH, Joondeph BC: Ophthalmology (CD-ROM Review). *Journal of the American Medical Association* 281:1547-1548, 1999.
41. Joondeph BC, Myint S, Joondeph HC: Positive Vitreous Cultures in Eyes with Retained Lens Fragments. *Retina* 19:354-355, 1999.
42. Desai UR, Tawansy KA, Joondeph BC, Schiffman RM: Choroidal Granuloma in Systemic Sarcoidosis. *Retina* 21:40-47, 2001.
43. Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS: Successful Treatment of Serpiginous Choroiditis with Alkylating Agents. *Ophthalmology* 109:1506-1513, 2002.
44. Jayasundera T, Vote B, Joondeph B: Golf-related Ocular Injuries. *Clinical and Experimental Ophthalmology* 31:110-113, 2003.
45. Teba FA, Mohr A, Eckardt C, Wong D, Kusaka S, Joondeph BC, Feron EJ, Stalmans P, van Overdam K, Melles GRJ: Trypan Blue Staining in Vitreo-Retinal Surgery. *Ophthalmology* 110:2409-2412, 2003.
46. Joondeph BC: Comment on 'Macular Hole Surgery with or without Indocyanine Green Stained Internal Limiting Membrane Peeling'. *Clinical and Experimental Ophthalmology* 32:119, 2004.
47. Vote BJ, Russell MK, Joondeph BC: Trypan Blue Assisted Vitrectomy. *Retina* 24:736-738, 2004
48. Joondeph BC: Sub-Tenon's Triamcinolone (letter). *Ophthalmology* 112:1481, 2005

49. Joondeph BC, Nguyen H: Ocular Coherence Tomography Findings with Retained Submacular Perfluoron. *Clinical and Experimental Ophthalmology* 34:85-86, 2006.
50. Joondeph BC: Diagnostic and Therapeutic Challenges. *Retina* 27:101-105, 2007.
51. Squirrell DM, Stewart AW, Joondeph BC, Danesh-Meyer HV, McGhee CN, Donaldson ML: Large Spot Sub-threshold Infrared Laser to Treat Diabetic Macular Edema. *Retina* 28:615-621, 2008.
52. Joondeph BC: Use of Membrane Blue in ILM and ERM Peeling. *Retinal Physician* 6:54-56, 2009.
53. Joondeph BC, Nguyen H, Politzer T, Weintraub A: Terson's Syndrome Managed With 25-Gauge Vitrectomy. *Ophthalmic Surgery, Lasers & Imaging* February 15, 2010.
54. Joondeph BC, Hawes M, Politzer T. Evaluation and Treatment of Some Common Medical Eye Conditions Encountered in Patients with TBI, Stroke and Other Neurological Conditions in an Acute Care Rehabilitation Hospital. *NeuroRehabilitation* 27:243-246, 2010.
55. Joondeph BC. Controlled Aspiration of Subfoveal Perfluorocarbon Liquid Using a Novel Microcannula. *Retina* 31:991-993, 2011.
56. Joondeph SA, Joondeph BC. Retinal Detachment Due to CrossFit Training Injury. *Case Reports in Ophthalmological Medicine* vol. 2013, Article ID 189837, 2 pages, 2013.
57. Joondeph BC. Anti-VEGF Injection Technique for Recurrent Exudative Macular Degeneration in a Telescope-Implanted Eye. *Retinal Cases and Brief Reports*, April 14, 2014.
58. Cao JH, Mulvalhill M, Zhang L, Joondeph BC, Dacey MS. Dexamethasone Intravitreal Implant in the Treatment of Persistent Uveitic Macular Edema in the Absence of Active Inflammation. *Ophthalmology* 121:1871-1876, 2014.
59. Joondeph BC. Ocular Trauma From the "Knockout Game". *Case Reports in Ophthalmological Medicine* vol. 2014, Article ID 285942, 2 pages, 2014.
60. Schlimgen M, Fortin MJ, Joondeph BC. OCT Imaging in Eyes with an Implanted Telescope. *Retina Today*, January/February 2015.
61. Zick J, Joondeph BC. Injecting and Imaging Patients With Wet AMD and Implanted Telescopes. *Retina Today*, May/June 2015.
62. Pappas A, Fortin M, Joondeph BC. SD-OCT Imaging in Eyes Implanted with a Miniature Telescope. *Retina Today*, July/August 2015.
63. Joondeph BC. Vitreoretinal Staining Solutions. *Retina Today*, September 2015.
64. Fortin MJ, Joondeph BC. Management of New or Recurrent Choroidal Neovascularization in Telescope-Implanted Eyes. *Journal of Ophthalmic Photography*, 37:70-72, 2015.
65. Joondeph BC. Will a New Low-Cost Option Join the Anti-VEGF Fold? *Retina Today*, April 2016.

66. Zick J, Joondeph BC. Is a postoperative day one examination needed after uncomplicated vitreoretinal surgery? *Retina* 38(2):331-333, February 2018.
67. Meredith G, Schkade P, Joondeph BC. Allergic Reaction upon Intravitreal Administration of anti-VEGF agents. *Retinal Cases & Brief Reports* Summer 2019, 13(3):287-289.
68. Leonard J, Bayne J, Joondeph BC. Using Pre-Health Professionals as Practice Support Staff. *Retina Today*, May/June 2017.
69. Joondeph BC. Further Refining the Ideal Macular Hole Repair. *Retina Today*, July/August 2017.
70. Joondeph BC. One Year in...Obamacare barely survived the first year of Trump's presidency. What will 2018 bring for ophthalmology and patients? *The Ophthalmologist*, February 2018.
71. Joondeph BC. The Jetrea Landscape at 6 Years. *Retinal Physician*, March 2018.
72. Joondeph BC. Is Macular Degeneration Slowly Going Away? *Retina Today*, May/June 2018.
73. Khanani A.M., Duker J.S., Heier J.S., Kaiser P.K., Joondeph B.C., Kozma P., Rosberger D.F., MacCumber M., Boyer D.S. & Pieramici D.J., Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study, *Ophthalmology Retina* 3:32-41, 2019.
74. Joondeph BC. Gas Bubbles and Altitude. *Retina Today*, September 2018.
75. Joondeph BC, Zick J. Reply to Letter to the Editor by Brennan, et al. *Retina*, 38:e87, 2018.
76. Grosso A, Scarpa G, Joondeph BC, et al. Choosing Wisely: Antibiotic Use in Ophthalmic Surgery. *Retina Today*, March 2019.
77. Joondeph, BC. Three and Out. *The Ophthalmologist*, February 2019.
78. Zick J, Dacey MS, Joondeph BC. As the Worm Turns. *Retina Today*, October 2019.
79. Webb M, Joondeph BC. An Elusive Macular Hole Closed by Eye Drops Alone. *Retina Today*, January/February 2020.
80. Atkinson CF, Patron ME, Joondeph BC. Retinal tears due to pickleball injury. *Retina Cases and Brief Reports*. (in press).
81. Khong J, Joondeph BC. A Novel Vitreous Culture Technique. *Retinal Cases & Brief Reports* (in press).
82. Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. *Ophthalmology* (in press).
83. Joondeph BC. US Retina Surgeons Can Stop Singing the Blues. *Retina Today* July/August 2020.

84. Joondeph BC, Charles M, Abulon D, Garg SJ, Kunimoto D. A 2020 Update on Vitrectomy Systems. *Retinal Physician*, November/December 2020.
85. Joondeph BC, Willems P, Raber T, Duchateau L, Markoff J. Prognostic Factors Associated With Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-Thickness Macular Hole: Analysis From Four Studies. *Journal of Ophthalmic and Vision Research* (in press).
86. Joondeph B, Adam M. Are you ready to get lean? *New Retinal Physician*, Nov/Dec 2020.
- 87.

BOOK CHAPTERS:

1. Joondeph BC: Blunt Ocular Trauma. In: Emergency Medicine Clinics of North America, Matthews J, Zun LS (eds). W.B. Saunders Co., Philadelphia, 6:147-167, 1988.
2. Joondeph BC, Peyman GA, Khoobehi B: Liposome-Encapsulated 5-Fluorouracil: A New Approach to Proliferative Vitreoretinopathy. In: Proliferative Vitreoretinopathy (PVR), Freeman HM, Tolentino FI (eds). Springer-Verlag Inc., New York, pp. 130-133, 1988.

CLINICAL TRIALS:

1. Richard-James Silicone Oil Study, **Principal Investigator**, 1990-95
2. Pneumatic Retinopexy Study II, **Prindipal Investigator**, 1990-92

3. Visudyne in Age-Related Macular Degeneration (VAM) Trial Visudyne T-IND Study, **Principal Investigator**, 2000
Sponsored by CIBA Vision Corp. and QLT PhotoTherapeutics Inc.
4. Trypan Blue Staining of Epiretinal Membranes During Vitrectomy
Sponsored by Netherlands Institute for Innovative Ocular Surgery and DORC. 2001-2. **Principal Investigator**.
5. Central Retinal Vein Occlusion Vitrectomy Study, New Zealand Multicenter Clinical Trial. 2002. **Principal Investigator**.
6. **Anecortave Acetate Therapy** for Age-Related Macular Degeneration Alcon Research Ltd. 2002-03. **Co-investigator**.
7. **MSI-1256F-209**- A Phase 2, Multi-center, Randomized, Masked, Controlled, Study of MSI-1256F (Squalamine lactate) for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration, sponsored by Genaera Corp, 2004-present. **Co-investigator**.
8. **VISIT (Novartis)** A Randomized, Double-Masked, Sham Controlled, Multicenter, Phase II Study Comparing the Safety and Efficacy of Photodynamic Therapy with Visudyne® Alone and Administered in Conjunction with Intravitreal Triamcinolone Acetonide in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (VisIT Study); Sponsored by Novartis Pharmaceuticals Corp, 2005-present. **Principal Investigator**.
9. **MSI-1256F-301**- A Phase 3, Multi-center, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration. **Co-investigator**.
10. **PTK** - Novartis Pharmaceuticals trial entitled: A randomized, double-masked, multicenter, phase I/II study of the safety of PTK787 administered in conjunction with photodynamic therapy with Visudyne® to patients with predominantly classic, minimally classic or occult with no classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. Protocol No.: PTK787 E2201. **Principal Investigator**.
11. **EYETECH DME** - PROTOCOL EOP1013: "A phase 2/3 randomized, controlled, double-masked, multi-center, comparative dose-finding trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of 0.3, 0.03 or 0.003 mg pegaptanib sodium (Macugen®), given as often as every 6 weeks for 3 years, to sham injections in subjects with diabetic macular edema (DME) involving the center of the macula". **Principal Investigator**.
12. **VERITAS (Novartis)** - Protocol No. BPD952E, entitled "A 24 month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration". **Principal Investigator**.
13. **AREDS II** – Age-related Eye Disease Study II (AREDS II): A multi-center, randomized trial of lutein, zeaxanthin and omega-3 fatty acid in age related macular degeneration. **Principal Investigator**.
14. **Posurdex (Allergan)** - A 6-Week, Phase 3, Multicenter, Masked, Randomized Trial (with a 20-Week

Masked Safety Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate Uveitis. **Principal Investigator.**

15. **Posurdes (Allergan)** - A 6-Week, Phase 3, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Safety Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-infectious Ocular Inflammation of the Anterior Segment in Patients with Anterior Uveitis. **Principal Investigator.**

16. **Posurdex (Allergan)** - A Phase 2, Multicenter, Masked, Randomized, Sham-Controlled 12-Month Trial (Plus a 12-Month Masked Extension) to Assess the Safety and Efficacy of a 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System as Adjunctive Therapy to Photodynamic Therapy with Verteporfin (PDT) in the Treatment of Patients with Age-Related Macular Degeneration (ARMD). **Sub-investigator.**

17. **FAME (Alimera)** - A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema. **Principal Investigator.**

18. **DENALI (Novartis)** - A 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. **Principal Investigator.**

19. **MacuSight** - A Phase 1, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of MS-R001 in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy. **Principal Investigator.**

20. **STOPCAT Trial (Othera)** - OT-551-002: A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel Group Evaluation of the Safety and Efficacy of OT-551 Ophthalmic Solution to Prevent Formation or Delay Progression of Nuclear Cataract Formation in Post-Vitrectomy Patients. **Principal Investigator.**

21. **LEVEL (Eyeteq)** - Protocol EOP1023: A Phase IV, open label, multi-center, trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular Age-Related Macular Degeneration (AMD) initially treated with a modality resulting in maculopathy improvement. **Sub-investigator.**

22. **Genentech through University of Utah - FVF4141s:** VEGF and HTRA1 DNA polymorphisms in neovascular AMD pathogenesis and response to Lucentis. **Sub-investigator.**

24. **Omega (Othera) OT-551-C04:** A randomized, double-masked, dose-ranging, multi-center, Phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration. **Principal Investigator.**

25. **AREDS 2** - The Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic acid [DHA] and Eicosapentaenoic acid [EPA]) in Age-Related Macular Degeneration **Principal Investigator**
26. **BRAVO (Genentech)** - FVF4165g: A Phase II multicenter, randomized sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion. **Sub-investigator.**
27. **CRUISE (Genentech)** - FVF4166g: A Phase III multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion. **Sub-investigator.**
28. **VIEW 1 (Regeneron) - VGFT-OD-0605**: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. **Principal Investigator.**
29. **Novartis CRAD01A2203** - A randomized, double-masked, parallel group study to assess the efficacy of oral Everolimus 5 mg once daily, either alone or added to Lucentis, in patients with neovascular age-related macular degeneration. **Principal Investigator**
30. **HORIZON – FVF3426g** – An Open Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who have Completed a Genentech-sponsored Ranibizumab Study. **Sub-Investigator**
31. **ThromboGenics – TG-MV-006** – A Randomized, Placebo-Controlled, Double-Masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. **Principal Investigator**
32. **MacuSight DIAMOND – DR002** - A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy. **Principal Investigator**
33. **Brimonidine (Allergan) DDS Optic Neuropathy Study (190342-030D)**. A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS[®]) Applicator System in Subjects with Primary Open Angle Glaucoma **Principal Investigator.**
34. **INSURE Study (Novartis) –CAIN457C2302** A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression. **Principal Investigator.**
35. **GSK - MD7110852**: A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. **Sub-Investigator**

36. **SEATTLE/Acucela: 4429-202-A** Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration (Geographic Atrophy) **Sub-Investigator.**
37. **AMPIO/OPTINA:** AP-05-002-A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOUBLE-MASKED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSES OF ORAL OPTINA™ IN ADULT PATIENTS WITH DIABETIC MACULAR EDEM. **Sub-Investigator.**
38. **BAM114341:**GSK- A phase 2, multi-centre, randomized, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) **Sub-Investigator.**
39. **NEI:** AMD Phenotype and Genotype Study- APGS-NIH-**Principal Investigator**
40. **OCULOS:** OHR-002-Phase 2 study of the efficacy and safety of Squalamine Lactate Ophthalmic Solution 0.2% twice daily in subjects with neovascular age-related macular degeneration. **Sub-Investigator.**
41. **REVIEW:** Regeneron-VGFTe-AMD-1124
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration. **Sub-Investigator.**
42. **STOP:** Genentech-ML28522- Study of the Safety, Tolerability, and Bioactivity of Tocilizumab on Patients with Non-infectious UVEITIS: The STOP-UVEITIS Study. **Sub-Investigator.**
43. **SAKURA DE-109:**SANTEEN-32-007-A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye. **Principal Investigator.**
44. **XOMA 130:** CLS-78989-005- A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis. **Sub-Investigator.**
45. **XOMA 131:** CLS-78989-006 -A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis Currently controlled with Systemic treatment. **Sub-Investigator.**
46. **FORSEE:** EMMES CORP. Home Vision Monitoring for Progression to Neovascular AMD Using the ForeseeHome Device. **Principal Investigator.**
47. **EYEGATE:** EGP-437-004. Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Non-Infectious Anterior Segment Uveitis. **Principal Investigator.**

48. **CAIN** (NOVARTIS) Protocol No.: CAIN457C2302

A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression (INSURE Study) **Sub-Investigator**.

49. **VISTA-Regeneron**- VGFT-OD-1009: A Double- Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trab-Eye in Patients with Diabetic Macular Edema. **Sub-Investigator**.

50. **HARBOR**- FVF4579g-Genentech . A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, ACTIVE TREATMENT–CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 0.5 mg AND 2.0 mg RANIBIZUMAB ADMINISTERED MONTHLY OR ON AN AS-NEEDED BASIS (PRN) IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. **Sub-Investigator**.

51. **SHORE**-FVF4967g-Genentech. A MULTICENTER RANDOMIZED STUDY EVALUATING DOSING REGIMENS FOR TREATMENT WITH INTRAVITREAL RANIBIZUMAB INJECTIONS IN SUBJECTS WITH MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION. **Sub-Investigator**.

52. **Radiant-Alzheimer**- I40 MC BACC A- Phase 2 Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer 's disease or Mild Alzheimer's Disease. **Sub-Investigator**.

53. **FOVISTA** - A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of FOVISTA™ (ANTI-PEGYLATED APTAMER) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration. **Principal Investigator**.

54. **FORSIGHT** - A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis. **Sub-Investigator**.

55. **AERPIO** - A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 months, as Monotherapy or Adjunctive to Ranibizumab, In Subjects with Diabetic Macular Edema. **Sub-Investigator**.

56. **TOGA** - A Randomized, Double-Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration. **Principal Investigator**.

57. **ORBIT** - Ocrlplasmin Research to Better Inform Treatment (ORBIT). **Principal Investigator**.

58. **STOP** - Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients with Non-Infectious Uveitis: The STOP study. **Sub-Investigator**.

59. **EYEGUARD** - A Randomized, Double-Masked, Placebo Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-Infectious Intermediate, Posterior, Or Pan-Uveitis (The EYEGUARD)-A study. **Sub-Investigator**.

60. **XOMA** - A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with non-infectious intermediate, posterior, or pan-uveitis currently controlled with systemic treatment. **Sub-Investigator.**
61. **SAKURA** - A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of The Posterior Segment of the Eye. **Principal Investigator.**
62. **DANAZOL** - A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients with Diabetic Macular Edema. **Sub-Investigator.**
63. **VISTA** - Double Masked, Randomized, Active Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap Eye in Patients with Diabetic Macular Edema. **Sub-Investigator.**
64. **BAM** - A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related macular Degeneration. **Sub-Investigator.**
65. **REGENERON** - An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Afibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration. **Sub-Investigator.**
66. **ACUCELA** - A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration. **Sub-Investigator.**
67. **OHR** - Phase 2 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. **Sub-Investigator.**
68. **NOVARTIS** - A randomized, active-controlled, open-label, multiple-dose, proof-of concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy. **Sub-Investigator.**
69. **AERPIO** - A phase 2, randomized, active-controlled, double-masked, multicenter study to assess the safety and efficacy of daily subcutaneous AKB-9778 administered for 3 months, as monotherapy or adjunctive to ranibizumab, in subjects with diabetic macular edema. **Sub-Investigator.**
70. **REINFORCE** - A prospective data collection study in patients receiving Ozurdex injections for diabetic macular edema. **Sub-Investigator.**
71. **LAMPA** - A phase 3, Randomized, Double-Masked, sham Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Lampalizumab Administered to patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. **Sub-Investigator.**
72. **EMERGE-(ICONIC)**: Protocol: IT-002, Title: A Phase II, Randomized, Double-Masked, Multicenter, Active-Controlled Study Evaluating the Safety of Repeated Intravitreal Injections of hL-con1 administered

as monotherapy or in combination with ranibizumab compared to ranibizumab monotherapy. **Sub-Investigator** 2015-present

73. **XCOVERY-Tyrogenex** Protocol: X82-OPH-201, Title: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea® monotherapy in Neovascular AMD. **Principal Investigator** 2015-present

74. **NEUROTECH**- Protocol: NT-503-3-AMD-001, Title: A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eylea® for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). **Principal Investigator** 2015-present

75. **LADDER** (Genentech)-Protocol: GX28228, Title: Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. **Sub-Investigator** 2015-present

76. **VIDI** (Astellas)-Protocol: 8232-CL-001, Title: A Phase II, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema. **Sub-Investigator** 2015-present

77. **HAWK** (Alcon): Protocol RTH258-C001, Title: A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Afibercept in Subjects with Neovascular Age-Related Macular Degeneration, **Principal Investigator** 2015-present

78. **CAPELLA** (Regeneron) Protocol: R2176-3-AMD-1417, Title: A Phase II, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176—3 in Patients with Neovascular Age-Related Macular Degeneration, **Sub-Investigator** 2015-present

79. **CEDAR** (Allergan): Protocol: AGN-150998, Title: A Multicenter, Double-Masked, Randomized 100-week, Parallel-Group, Active-Controlled Study to Evaluate the Safety and Efficacy of Abicipar in Treatment-Naïve patients with Neovascular AMD. **Sub-Investigator** 2015-present

80. **VAPOR** (Santen) Protocol: 35-002: Title: A Multicenter, Randomized, Open Label, Phase IIa Study Assessing the Efficacy, Safety and Duration of Effect on Intravitreal Injections of DE-120 (a VEGF and PDGF Receptor Inhibitor) as Monotherapy and with a Single Eyelea® Injection in Subjects with Treatment-Naïve Exudative Age-Related Macular Degeneration. **Principal Investigator** 2015-present

81. **ALDEYRA** (Aldeyra) Protocol: NS2-02, Title: A Phase 2, Randomized, Investigator-Masked, Comparator Controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients with Anterior Uveitis. **Sub-Investigator** 2015-present

82. **AVENUE** (Roche) Protocol: BP29647, Title: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. **Sub-Investigator** 2015-present

83. **PROXIMA** (Genentech) Protocol: GX29633, Title: A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. **Sub-Investigator** 2015-present

84. **LHA510** (Alcon/Novartis) Protocol: LHA510-2201, Title: A Randomized, Double-Masked, Vehicle-Controlled, Proof-of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients with Wet Age-Related Macular Degeneration. **Principal Investigator** 2015-present

85. **AURA** (Aura Biosciences) Protocol: AU-011-201 Title: A Prospective, Randomized, Multi-Center, Masked Clinical Trial Designed to Evaluate Two Doses of Light-Activated AU-011 for the Treatment of Subjects with Small to Medium (1.5-4.0 mm thickness) Primary Uveal Melanoma. Sub-Investigator 2016

LECTURES AND PRESENTATIONS:

1987

- March 4 "Retinal Macroaneurysm Treated with the Yellow Dye Laser"
Illinois Eye and Ear Infirmary Clinical Challenges Day; Chicago, IL
- May 5 "Foveal Neovascularization in Diabetic Retinopathy" (poster)
Association for Research in Vision and Ophthalmology (ARVO); Sarasota, FL
- May 20 "Familial Iris Melanosis - A Misnomer"
Illinois Eye and Ear Infirmary Resident/Alumni Day; Chicago, IL
- Nov 8 "Liposome-Encapsulated 5-Fluorouracil in the Treatment of Proliferative Vitreoretinopathy" (poster)
American Academy of Ophthalmology Annual Meeting; Dallas, TX

1988

- March 9 "Peripapillary Choroidal Neovascularization Associated with Pseudotumor Cerebri"
Illinois Eye and Ear Infirmary Clinical Challenges Day; Chicago, IL
- May 2 "Familial Iris Melanosis - A Misnomer?" (poster)
ARVO; Sarasota, FL
- May 25 "Liposome-Encapsulated 5-Fluorouracil in the Treatment of Proliferative Vitreoretinopathy"
Illinois Eye and Ear Infirmary Resident/Alumni Day; Chicago, IL
- Nov 12 "Hypertensive Retinopathy and Retinal Arterial Occlusive Disease"
Joint Commission of Allied Health Personnel Organization (JCAHPO)

Regional Continuing Education Program for the Ophthalmic Medical Assistant; Miami, FL

1989

- Feb 25 "Hemostatic Effects of Air Versus Fluid in Diabetic Vitrectomy"
Bascom Palmer Eye Institute 25th Annual Residents Day; Miami, FL
- May 5 "A New Culture Method for Infectious Endophthalmitis" (poster)
ARVO; Sarasota, FL
- July 22 "Penetrating Ocular Trauma"
University of Illinois Eye Trauma Symposium; Chicago, IL
- Sept 22 "Vitreous Culture Methods for Endophthalmitis"
University of Illinois Eye Center Annual Meeting; Chicago, IL
- Oct 28 "A New Culture Method for Infectious Endophthalmitis"
Ocular Microbiology and Immunology Group Annual Meeting;
New Orleans, LA
- Oct 31 "Hemostatic Effects of Air Versus Fluid in Diabetic Vitrectomy"
American Academy of Ophthalmology Annual Meeting; New Orleans, LA
- Dec 9 "A New Culture Method for Infectious Endophthalmitis"
Vitreous Society Annual Meeting; Orlando, FL

1990

- May 23 "Misdiagnosis of Impending Macular Holes"
University of Illinois at Chicago (UIC) Resident - Alumni Day Meeting;
Chicago, IL
- Aug 11 "Diagnosis of Endophthalmitis"
Michigan Ophthalmological Society Annual Summer Conference;
Mackinac Island, MI
- Oct 27 "Combined Retinal/RPE Hamartoma"
Fluorescein Reading and Macular Evaluation (FRAME) Meeting; Atlanta, GA
- Oct 29 "Delayed-Onset Pseudophakic Endophthalmitis"
American Uveitis Society Meeting; Atlanta, GA

1991

- May 30 "Delayed-Onset Pseudophakic Endophthalmitis"
University of Illinois Resident/Alumni Day; Chicago, IL

- June 1 "Delayed-Onset Pseudophakic Endophthalmitis"
Kresge Eye Institute Clinical Days Conference; Detroit, MI
- June 10 "Posterior Uveitis and Endophthalmitis"
Kresge Eye Institute Resident Lecture Series; Detroit, MI
- June 22 "Management of Subretinal Foreign Bodies with a Cannulated Extrusion
Needle"
Bascom Palmer Eye Institute Annual Residents Day; Miami, FL
- Oct 12 "Cilioretinal Artery Occlusion with Central Retinal
Vein Occlusion" FRAME Annual Meeting; Anaheim, CA
- Oct 14 "A New Technique for the Administration of Intraoperative Periocular Steroids"
American Uveitis Society Meeting; Anaheim, CA

1992

- March 11 "Diabetic Retinopathy"
First Optometry Lecture Series; Troy, MI
- May 13 "Macular Degeneration"
First Optometry Lecture Series; Troy, MI
- May 15 "Management of Subretinal Foreign Bodies with a Cannulated Extrusion
Needle"
University of Illinois Resident/Alumni Day; Chicago, IL
- May 29 "Management of Subretinal Foreign Bodies with a Cannulated Extrusion
Needle"
Kresge Eye Institute Clinical Days Conference; Detroit, MI
- July 1 "Retinal Vascular Diseases"
First Optometry Lecture Series; Troy, MI
- Sept 2 "Diabetic Retinopathy"
St. John Hospital Department of Medicine Conference; Detroit, MI
- Oct 14 "Vitreoretinal Diseases"
First Optometry Lecture Series; Troy, MI
- Oct 20 "Comparison of Three Permanent Intraocular Magnets"
Vitreous Society Annual Meeting; Laguna, CA

1993

- Jan 24 "Vitreoretinal Diseases"
Fraser Eye Care Center Retina Update; Fraser, MI

- Oct 6 "Binocular Indirect Ophthalmoscopy:
First Optometry Lecture Series; Troy, MI
- Oct 25 "Diabetic Retinopathy"
Port Huron Hospital Medical Staff Conference; Port Huron, MI
- Nov 2 "Vitreo-Retinal Surgery"
Association of Operating Room Nurses; Southfield, MI
- Nov 3 "Indirect Ophthalmoscopy Practical"
First Optometry Lecture Series; Roseville, MI
- Nov 13 "Idiopathic Uveal Effusion Syndrome"
FRAME Annual Meeting; Chicago, IL

1994

- May 13 "Concurrent Endophthalmitis and Retinal Detachment"
University of Illinois Resident/Alumni Day; Chicago, IL
- June 1 "Intraocular Lens Complications"
First Optometry Lecture Series; Roseville, MI
- June 8 "Vitreo-Retinal Surgery"
Association of Operating Room Nurses; Clinton Township, MI
- June 17 "Subclinical Endophthalmitis Following Cataract Extraction with
Retained Lens Cortex"
Kresge Eye Institute Clinical Days Conference; Detroit, MI
- Aug 16 "Subclinical Endophthalmitis Following Cataract Extraction with
Retained Lens Cortex"
Vitreous Society Annual Meeting; Aspen, CO
- Oct 21 "Diabetic Retinopathy"
St. John Hospital Dept. of Family Practice; Detroit, MI

1995

- Jan 12 "Vitreo-Retinal Surgery"
Association of Operating Room Nurses; Detroit, MI
- Mar 5 "Update on Diabetic Retinopathy" "Complications of Intraocular
Lenses" Metro 95: Ophthalmology Update; Troy, MI
- April 6 "Diabetic Retinopathy"
St. John Hospital Department of Medicine; Detroit, MI

Sept 6 "Intraocular Lens Complications"
Optometry Lecture Series; St. Clair Shores, MI

Oct 28 "Unilateral Acute Idiopathic Maculopathy"
FRAME Annual Meeting; Atlanta, GA

1996

Mar 17 "Retinal Vascular Diseases"
"Macular Degeneration Update"
Metro 96: Ophthalmology Update; Troy, MI

May 24 "Diabetic Retinopathy"
St. John Hospital Hospital Transplant Department; Detroit, MI

June 3 "Endophthalmitis"
Kresge Eye Institute; Detroit, MI

June 21 "Delayed-onset Endophthalmitis"
Kresge Eye Institute Resident's Day Conference; Detroit, MI

July 10 "Macular Degeneration Update"
Optometry Lecture Series; St. Clair Shores, MI

Aug 12 "Macular Degeneration Update"
Bon Secours Hospital; Grosse Pointe, MI

Oct 14 "Diabetic Retinopathy Update"
Bon Secours Hospital; Grosse Pointe, MI

Oct 26 "Unusual Central Serous Chorioretinopathy"
FRAME Annual Meeting; Chicago, IL

Oct 29 "Subclinical Endophthalmitis Following Cataract Extraction with
Retained Lens Cortex"
American Academy of Ophthalmology Annual Meeting; Chicago, IL

1997

April 15 "Vitreoretinal Surgery Update"
Cottage Hospital; Grosse Pointe, MI

June 13 "Subclinical Endophthalmitis Following Cataract Extraction with
Retained Lens Cortex"
Kresge Eye Institute Annual Clinical Conference; Southfield, MI

1999

March 10 "Endophthalmitis"

Kresge Eye Institute; Detroit, MI

Sept 9 "Macular Degeneration"
St. John Hospital; Detroit, MI

2000

Dec 3 "Prolonged Remission of Serpiginous Choroiditis with High-Dose Short-Term
Chlorambucil"
Retina Society Annual Meeting; Miami, FL

2001

March 3 "Prolonged Remission of Serpiginous Choroiditis with High-Dose Short-Term
Chlorambucil"
Macula Society Annual Meeting; Scottsdale, AZ

May 5 "Retina Update"
St. Joseph's Mercy Hospital; Clinton Township, MI

Nov 16 "Visiting Professor"
Waikato Hospital Dept. of Ophthalmology; Hamilton, NZ

Dec 4 "Idiopathic Uveitis and Treatment of Uveitis"
RANZCO Part II Course, Univ of Auckland; Auckland, NZ

Dec 7 "Posterior Segment Trauma"
RANZCO Part II Course, Univ of Auckland; Auckland, NZ

2002

April 9 "Vitreoretinal Update 2002"
New Zealand Association of Optometrists Meeting; Auckland, NZ

April 22 "Successful Treatment of Serpiginous Choroiditis with Alkylating Agents"
International Congress of Ophthalmology; Sydney, Australia

July 4 "Vitreoretinal Surgery 2002"
Ophthalmic Nurses Course 2002; Auckland, NZ

Aug 1-3 "Vitreoretinal Poker"
"Slit Lamp Examination of the Posterior Segment"
Snowvision Down Under 2002 (**Invited Speaker**); Queenstown, NZ

Aug 10 "Anterior Segment Ischemia"
MSD Clinical Colloquium; Queenstown, NZ

Sept 28-Oct 2 "Trypan Blue Membrane Staining in Vitreoretinal Surgery" (paper)

“Focal Laser Treatment for Diabetic Macular Edema” (poster)
“Trypan Blue as an Adjuvant in Vitreo-Retinal Surgery” (poster)
“Golf Related Ocular Injuries” (poster)
“A Technique for Maximizing Silicone Oil Fill” (poster)
“South Auckland Diabetic Retinopathy Study” (poster)
Retina Congress 2002; San Francisco, CA

2003

May 9 “Trypan blue Membrane Staining in Vitreo-Retinal Surgery”
RANZCO NZ Branch Meeting 2003; The Chateau, NZ

August 16 “Macular Degeneration”
Women’s Health Fair; Wheat Ridge, CO

October 4 “Macular Degeneration – What’s New on the Horizon”
7th Annual Low Vision Expo; Colorado Springs, CO

November 3 “Macular Degeneration Update”
Novartis Regional Symposium; Lone Tree, CO

November 5 “Macular Degeneration Update”
Novartis Regional Symposium; Arvada, CO

November 18 “Trypan Blue Staining in Vitreo-Retinal Surgery – Educational Course”
American Academy of Ophthalmology Annual Meeting; Anaheim, CA

November 19 “Macular Degeneration Update”
Novartis Regional Symposium; Denver, CO

November 20 “Macular Degeneration Update”
Novartis Regional Symposium; Lone Tree, CO

2004

Jan 17-21 “Update in Retina and Glaucoma Imaging”
“Vitreo-Retinal Poker”
“Slit-lamp Examination of the Vitreous and Retina”
“Retina Grand Rounds”
SnowVision 2004 (**Invited Speaker**); Whistler, British Columbia

Feb 24 “Slit-lamp Examination of the Posterior Segment”
Rocky Mountain Ophthalmic Personnel; Denver, CO

Oct 3 “Endophthalmitis after Pars Plana Vitrectomy”
Retina Society Meeting; Baltimore, MD

Oct 26 “Trypan Blue Staining in Vitreo-Retinal Surgery”
American Academy of Ophthalmology Annual Meeting; New Orleans, LA

2005

- March 18 "AMD Update"
SnowVision 2005 (**Invited Speaker**); Vail, CO
- June 18 "Chemotherapy for AMD"
Univ of Colorado Residents/Alumni Day; Denver, CO
- Oct 16 "Choroidal Hemangioma"
1st Annual Ocular Imaging Conference; Chicago, IL
- Oct 17 "Scleral Buckle for Primary Retinal Detachment"
American Academy of Ophthalmology Annual Meeting; Chicago, IL

2006

- March 22 "Combination Therapy for Macular Degeneration"
Rocky Mountain Ophthalmic Personnel; Denver, CO
- April 24 "AMD and Retisert Update"
Rapid City Retina Community; Rapid City, SD
- June 17 "Pharmacologic Therapy for Diabetic Macular Edema"
Univ of Colorado Annual Research Day; Denver, CO
- June 20 "AMD Update"
Goodland Medical Community; Goodland, KS
- Aug 17 "Retisert Update"
Denver Retina Community; Denver, CO
- Aug 28 "AMD Update"
Fargo Retina Community; Fargo, ND
- Oct 18 "Advance Study Update"
Retina Society Annual Meeting; Capetown, SA
- Nov 12 "Terson's Syndrome"
2nd Annual Ocular Imaging Conference; Las Vegas, NV
- Nov 12 "Advance Study Update"
American Academy of Ophthalmology; Las Vegas, NV
- Dec 13 "Retisert Update"
Southern California Kaiser Group; Los Angeles, CA

2007

- Feb 5 "AMD Update and Combination Therapy"
St Louis Retina Community; St Louis, MO
- March 15 "Induction/Maintenance Therapy"
Santa Barbara Ophthalmology Society Meeting; Santa Barbara, CA
- March 30 "AMD Update and Combination Therapy"
Richmond Retina Community; Richmond, VA
- May 14 "Managing the AMD Patient for Long Term Success"
Los Angeles Retina Community; Los Angeles, CA
- May 16 "Managing the AMD Patient for Long Term Success"
Denver Retina Community; Denver, CO
- June 11 "Managing the AMD Patient for Long Term Success"
Kansas City Retina Community; Kansas City, MO
- June 16 "OT-551 – A New Anti-oxidant, Anti-Inflammatory, Anti-angiogenic Eye Drop"
Univ of Colorado Annual Research Day; Denver, CO
- July 30 "Managing the AMD Patient for Long Term Success"
UCLA Residents and Fellows; Santa Monica, CA
- Oct 30 "Anti-VEGF in Retinal Disease and Practice Management Issues"
Cleveland Retina Community; Cleveland OH
- Nov 28 "Anti-VEGF in Retinal Disease and Practice Management Issues"
Dallas Retina Community; Dallas, TX
- Dec 2 "Combination Therapy with Verteporfin PDT and Anti-VEGF for Wet Age-Related
Macular Degeneration"
ASRS Annual Meeting; Indian Wells, CA
- Dec 5 "Management of Terson's Syndrome with 25-Gauge Vitrectomy"
ASRS Annual Meeting; Indian Wells, CA
- Dec 17 "Anti-VEGF in Retinal Disease and Practice Management Issues"
Portland Retina Community; Portland, OR

2008

- Feb 19 "AMD Management"
Denver Retina Community; Denver, CO
- March 10 "AMD Management"
Denver Ophthalmology Community; Denver, CO

- March 21 "AMD Management"
Porter Adventist Hospital; Denver, CO
- March 27 "AMD Management"
Denver Optometric Community; Denver, CO
- April 27 "Combination Therapy with Verteporfin PDT and Anti-VEGF for Wet Age-Related
Macular Degeneration"
ARVO Annual Meeting; Fort Lauderdale, FL
- August 28 "Endophthalmitis Update 2008"
Porter Hospital Dept of Ophthalmology; Denver CO
- September 26 "Combination Therapy with Verteporfin PDT and Anti-VEGF for Wet Age-Related
Macular Degeneration"
Retina Society Annual Meeting; Scottsdale, AZ

2010

- March 30 "Retina Update 2010"
RMOP; Denver, CO
- June 19 "Current Treatments for AMD"
Ophthalmic Photographers Society Annual Meeting; Denver, CO
- June 23 "Steroids in Uveitis and Retinal Disease"
Denver Ophthalmology Community; Denver, CO
- October 19 "Membrane Staining in Vitrectomy Surgery" (course)
American Academy of Ophthalmology Annual Meeting; Chicago, IL
- November 29 "Ozurdex for Uveitis and RVO"
Omaha Retina Community; Omaha, NB

2011

- February 13 "Cataract Surgery Complications" (Meeting Director)
Mile High Masters of Retina 2011; Denver, CO
- June 16 "Ozurdex for Uveitis and RVO"
Denver Retina Community; Denver, CO
- October 8 "A Day in the Life of a Retina Surgeon: Common Cases and Management"
Specialty Eye Center CE Meeting; Lafayette, CO

2012

- February 12 "Beyond Squirtology – New Approaches to AMD" (Meeting Director)
Mile High Masters of Retina 2012; Denver, CO

August 24 "Retinal Detachment Management – Tips and Tricks"
Seeing is Believing, Dutch Ophthalmic; Las Vegas, CO

2013

February 10 "Endophthalmitis – Pearls for Prevention, Diagnosis, and Treatment"
Mile High Masters of Retina 2013; Denver, CO

August 23 United Nations of Retina, Panel Discussion
DORC Live Surgery Toronto; Toronto, ON

November 1 "The Quest for Quality: Shifting the Culture Toward Quality Measurement Within a
Group Medical Practice"
Healthcare Quality Coalition of Colorado; Denver, CO

2014

February 9 "Macular Degeneration in 3 Easy Steps"
Mile High Masters of Retina 2014; Denver, CO

May 8 "Quality Measures Within a Group Retina Practice "
ARVO Annual Meeting; Orlando, FL

August 11 "Quality Measures Within a Group Retina Practice "
American Society of Retinal Specialists Annual Meeting; San Diego, CA

Sept 12 "Quality Measures Within a Group Retina Practice "
Retina Society Annual Meeting; Philadelphia, PA

Oct 9 "Ozurdex for DME"
Denver Retina Community; Denver, CO

Oct 19 "Quality Measures Within a Group Retina Practice "
American Academy of Ophthalmology Annual Meeting; Chicago, IL

Oct 24 "The Quest for Quality: Three Sides of the Triple Aim Triangle"
Healthcare Quality Coalition of Colorado Symposium; Denver, CO

Nov 17 "Ocriplasmin Advisory Board"
Denver Retina Community; Denver, CO

Dec 3 "Ocriplasmin Advisory Board"
Dallas Retina Community; Dallas, TX

2015

- Feb 8 "Macular Surgery – An Update 2015"
Mile High Masters of Retina; Denver, CO
- Feb 27 "Quality Measurement Within a Group Retina Practice"
Macula Society Annual Meeting; Scottsdale, AZ
- May 6 "Is the Postoperative Day One Examination Necessary after Uncomplicated
Vitreoretinal Surgery?"
ARVO Annual Meeting; Denver, CO
- Nov 14 "Wet AMD Management through the IMT: Best Practices"
VisionCare VIP/Users Meeting; Las Vegas, NV
- Nov 15 "IILM Flap for Macular Hole"
OIC Imaging Conference; Las Vegas, NV

2016

- January 7 "Single Payer Health Care"
Libertarian Party of Boulder County; Boulder, CO
- February 7 "Cataract Surgery and the Retina"
Mile High Masters of Retina; Denver, CO
- May 3 "ORBIT: A Phase IV Clinical Study – Lessons Learned from Patient Selection
Criteria for Ocricplasmin Intravitreal Injection"
ARVO Annual Meeting; Seattle, WA
- August 9 "Wet AMD Management Through the Implantable Miniature Telescope"
"Is the Postoperative Day One Examination Necessary After Uncomplicated
Vitreoretinal Surgery?"
ASRS Annual Meeting; San Francisco, CA
- September 15 "Management of Choroidal Neovascularization (CNV) through the Implantable
Miniature Telescope (IMT)"
Retina Society Annual Meeting; San Diego, CA

2017

- February 12 "Intravitreal Injections"
Mile High Masters of Retina; Denver, CO
- May 9 "Efficacy and Safety Outcomes from the ORBIT Phase IV Clinical Study"
ARVO Annual Meeting; Baltimore, MD
- June 9 "The SAKURA Program: Corticosteroid Tapering Success With Every-Other-Month
Intravitreal Sirolimus for Non-infectious Uveitis of the Posterior Segment"
Macula Society Annual Meeting; Singapore

2018

- February 11 "Doctor I Have New Floaters. What Does That Mean?"
Mile High Masters of Retina; Denver, CO
- April 29 "Post-Hoc Comparison of Best-Corrected Visual Acuity Improvement in Study and
Untreated Fellow Eyes with Active Non-Infectious Uveitis of the Posterior Segment in
the SAKURA Program"
ARVO Annual Meeting; Honolulu, HI
- July 21 "AntiVEGF in 2018 – From Studies to the Real World"
Christian Ophthalmology Society Annual Meeting; Estes Park, CO

2019

- February 10 "Why Can't I See Better After My Cataract Surgery?"
"ILM Patch for Macular Hole"
Mile High Masters of Retina, Denver, CO
- February 16 "Effect of Intravitreal Sirolimus on Visual Acuity in Subjects with Active Non-infectious
Uveitis of the Posterior Segment of the Eye: Results of the SAKURA Program"
Macula Society Annual Meeting; Naples, FL

2020

- February 9 "Macular Degeneration – Update 2020"
"Anti-VEGF Injections and Cataract/IOL Complications"
Mile High Masters of Retina; Denver, CO
- September 8 ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - Phase 1 OPTIC Study
Update
Retina Society Annual Meeting; Virtual